HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
HemoGenyx Pharmaceuticals has successfully completed a crucial site initiation visit for its Phase I clinical trial of HG-CT-1, a promising treatment for relapsed/refractory acute myeloid leukemia (AML). This milestone sets the stage for patient recruitment and highlights the company’s commitment to developing innovative therapies for blood diseases with limited treatment options. The trial aims to explore the safety and potential of HG-CT-1, leveraging CAR-T cell therapy to improve outcomes for AML patients.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.